Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154K | $1.60M | $30.3M | $40.9M | $108M | $210M | $157M | $146M | $145M | $146M |
| Revenue growth | — | 942.2% | 1790.1% | 34.8% | 164.3% | 94.1% | -25.1% | -7.0% | -0.5% | 0.6% |
| Operating income | -$111M | -$131M | -$180M | -$189M | -$172M | -$98.3M | -$142M | -$130M | -$119M | -$90.7M |
| Operating margin | -71903.9% | -8133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% |
| Net income | -$110M | -$129M | -$178M | -$200M | -$196M | -$124M | -$165M | -$143M | -$76.4M | -$196M |
| Net margin | -71153.9% | -8036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% |
| EPS (diluted) | -$2.92 | -$2.81 | -$3.14 | -$3.22 | -$2.72 | -$1.65 | -$2.02 | -$18.79 | -$14.00 | -$17.93 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$84.4M | -$73.7M | -$159M | -$191M | -$160M | -$107M | -$150M | -$92.7M | -$127M | -$75.4M |
| Capital expenditures | $70.0K | $62.0K | $2.36M | $206K | $145K | $212K | $118K | $0.00 | $142K | $0.00 |
| Free cash flow | -$84.5M | -$73.8M | -$161M | -$191M | -$160M | -$107M | -$150M | -$92.7M | -$128M | -$75.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $49.7M | $69.0M | $118M | $129M | $85.9M | $190M | $135M | $52.2M | $62.5M | $60.5M |
| Total assets | $180M | $180M | $341M | $295M | $313M | $305M | $358M | $240M | $164M | $108M |
| Total liabilities | $18.1M | $50.8M | $158M | $245M | $263M | $385M | $375M | $377M | $350M | $401M |
| Long-term debt | — | — | — | — | — | $169M | — | — | — | — |
| Shareholders' equity | $162M | $129M | $183M | $49.8M | $50.5M | -$79.7M | -$16.7M | -$136M | -$186M | -$293M |
| Retained earnings | -$366M | -$495M | -$674M | -$873M | -$1.07B | -$1.18B | -$1.34B | -$1.49B | -$1.56B | -$1.76B |
| Shares (wtd avg diluted) | 41.9M | 49.5M | 60.8M | 65.4M | 72.0M | 75.2M | 81.9B | 7.62B | 8.46B | 10.9B |
Every figure is extracted from Karyopharm Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.